title: Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
abstract: The fate of naive CD8(+) T cells is determined by the environment in which they encounter MHC class I presented peptide Ags. The manner in which tumor Ags are presented is a longstanding matter of debate. Ag presentation might be mediated by tumor cells in tumor draining lymph nodes or via cross-presentation by professional APC. Either pathway is insufficient to elicit protective antitumor immunity. We now demonstrate using a syngeneic mouse tumor model, expressing an Ag derived from the early region 1A of human adenovirus type 5, that the inadequate nature of the antitumor CTL response is not due to direct Ag presentation by the tumor cells, but results from presentation of tumor-derived Ag by nonactivated CD11c(+) APC. Although this event results in division of naive CTL in tumor draining lymph nodes, it does not establish a productive immune response. Treatment of tumor-bearing mice with dendritic cell-stimulating agonistic anti-CD40 mAb resulted in systemic efflux of CTL with robust effector function capable to eradicate established tumors. For efficacy of anti-CD40 treatment, CD40 ligation of host APC is required because adoptive transfer of CD40-proficient tumor-specific TCR transgenic CTL into CD40-deficient tumor-bearing mice did not lead to productive antitumor immunity after CD40 triggering in vivo. CpG and detoxified LPS (MPL) acted similarly as agonistic anti-CD40 mAb with respect to CD8(+) CTL efflux and tumor eradication. Together these results indicate that dendritic cells, depending on their activation state, orchestrate the outcome of CTL-mediated immunity against tumors, leading either to an ineffective immune response or potent antitumor immunity.
authors.affiliation: Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Geertje J D
authors.initials: GJ
authors.lastname: van Mierlo
authors.forename: Zita F H M
authors.initials: ZF
authors.lastname: Boonman
authors.forename: Hélène M H
authors.initials: HM
authors.lastname: Dumortier
authors.forename: Annemieke Th
authors.initials: AT
authors.lastname: den Boer
authors.forename: Marieke F
authors.initials: MF
authors.lastname: Fransen
authors.forename: Jan
authors.initials: J
authors.lastname: Nouta
authors.forename: Ellen I H
authors.initials: EI
authors.lastname: van der Voort
authors.forename: Rienk
authors.initials: R
authors.lastname: Offringa
authors.forename: René E M
authors.initials: RE
authors.lastname: Toes
authors.forename: Cornelis J M
authors.initials: CJ
authors.lastname: Melief
mesh_terms: D017500:Adenovirus E1A Proteins / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism; D000957:Antigens, Viral, Tumor / Q000276:immunology / Q000378:metabolism*; D039521:CD11c Antigen / Q000096:biosynthesis; D019013:CD40 Antigens / Q000096:biosynthesis / Q000276:immunology; D045142:Cross-Priming / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000378:metabolism; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000517:prevention & control*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D017500:Adenovirus E1A Proteins; D000911:Antibodies, Monoclonal; D000957:Antigens, Viral, Tumor; D039521:CD11c Antigen; D019013:CD40 Antigens; D018984:Epitopes, T-Lymphocyte